FindTrial
Sign In

A clinical trial to study the preventive effect of zoledronic acid therapy on drug induced bone loss in breast cancer

Effect of zoledronic acid therapy on aromatase inhibitor induced bone loss in postmenopausal Hormone Responsive Early Breast Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/09/004943
Enrollment
20
Registered
2014-09-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- postmenopausal hormone receptor positive early breast cancer (stage I-IIIA) patients, who had had primary surgery, did not have recurrent or metastatic disease treated with aromatase inhibitor

Interventions

Intervention1: Zoledronic acid: 5 mg i.v. stat once Control Intervention1: Not Applicable: Not applicable

Sponsors

Dr Ved Prakash
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: postmenopausal hormone receptor positive early breast cancer (stage I-IIIA) patients, who had had primary surgery, did not have recurrent or metastatic disease and treated with aromatase inhibitor

Exclusion criteria

Exclusion criteria: Male Premenopausal Advanced disease

Design outcomes

Primary

MeasureTime frame
Serum C-terminal telopeptide level Serum alkaline phosphatase levelTimepoint: 6 months—

Secondary

MeasureTime frame
Lumbar spine Bone mineral densityTimepoint: 1 year—

Countries

India

Contacts

Public ContactDr NK Agrawal

Institute of Medical Sciences

drnkavns@gmail.com9415224741

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026